XOMA has built a significant portfolio of products that are licensed to and being developed by other biotechnology and pharmaceutical companies. The Company’s portfolio of partner-funded programs spans multiple stages of the drug development process and across various therapeutic areas. Many of these licenses are the result of XOMA’s pioneering efforts in the discovery and development of antibody therapeutics. The Company’s royalty-aggregator business model includes acquiring additional licenses to programs with third-party funding. For more information, visit www.xoma.com.
All references to “portfolio” in XOMA’s posts refer strictly to milestone and/or royalty rights associated with a basket of drug products in development. All references to “assets” in XOMA’s posts refer strictly to milestone and/or royalty rights associated with individual drug product candidates in development. References to royalties or royalty rates in XOMA’s posts strictly refer to future potential payment streams regardless of whether or not they are technically defined as royalties in the underlying contractual agreement; further, any rates referenced herein are subject to potential future contractual adjustments.
All references to “portfolio” in XOMA’s posts refer strictly to milestone and/or royalty rights associated with a basket of drug products in development. All references to “assets” in XOMA’s posts refer strictly to milestone and/or royalty rights associated with individual drug product candidates in development. References to royalties or royalty rates in XOMA’s posts strictly refer to future potential payment streams regardless of whether or not they are technically defined as royalties in the underlying contractual agreement; further, any rates referenced herein are subject to potential future contractual adjustments.
Location: United States, California, Emeryville
Employees: 11-50
Founded date: 1981
Investors 2
| Date | Name | Website |
| - | Hercules C... | htgc.com |
| - | Ignite 500 | ignite500.... |
Mentions in press and media 17
| Date | Title | Description |
| 19.12.2024 | XOMA Royalty Declares Quarterly Preferred Stock Dividends | EMERYVILLE, Calif., Dec. 19, 2024 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (Nasdaq: XOMA) today announced its Board of Directors has authorized the following cash dividends to holders of XOMA’s Series A and Series B Cumulative Preferred... |
| 07.11.2024 | XOMA Royalty Reports Third Quarter 2024 Financial Results and Highlights Recent Activities | Zevra’s MIPLYFFA™ (arimoclomol) received FDA approval and became the sixth commercial asset in XOMA Royalty’s portfolio XOMA Royalty acquired a 50 percent economic interest in TWIST Bioscience’s portfolio of 60-plus licensed early-stage ass... |
| 20.06.2024 | XOMA Declares Quarterly Preferred Stock Dividends | EMERYVILLE, Calif., June 20, 2024 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq: XOMA) (“XOMA” or the “Company”) today announced its Board of Directors has authorized the following cash dividends to holders of XOMA’s Series A and Series B Cu... |
| 03.04.2024 | XOMA Corporation Announces Closing of Tender Offer | Kinnate Stockholders to Receive $2.5879 Per Share in Cash Plus Contingent Value Right EMERYVILLE, Calif., April 03, 2024 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA) (“XOMA” or the “Company”), a biotechnology royalty aggregator playi... |
| 08.03.2024 | XOMA Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent and Upcoming Events Expected to Drive Shareholder Value | - |
| 07.01.2023 | XOMA Announces New Employment Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | EMERYVILLE, Calif., Jan. 06, 2023 (GLOBE NEWSWIRE) -- XOMA Corporation XOMA ("XOMA" or the "Company"), the Biotech Royalty Aggregator, today announced the Company has granted Owen Hughes, the Company's newly appointed Ex... |
| 07.09.2022 | XOMA to Present at H.C. Wainwright 24th Annual Global Investment Conference | EMERYVILLE, Calif., Sept. 07, 2022 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq: XOMA), a biotechnology royalty aggregator playing a distinctive role in helping companies achieve their goal of improving human health, announced today its Cha... |
| 04.08.2022 | XOMA Reports Second Quarter 2022 Financial Results and Highlights Recent Operational Events | The completion of Regeneron’s acquisition of Checkmate Pharmaceuticals resulted in a $5 million milestone payment to Kuros, $2.5 million of which was paid to XOMA in July. Data from Rezolute and Day One led both companies to announce plans ... |
| 20.06.2022 | XOMA Declares Quarterly Preferred Stock Dividends | EMERYVILLE, Calif., June 20, 2022 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq: XOMA) (“XOMA” or the “Company”) today announced its Board of Directors has authorized the following cash dividends to holders of XOMA’s Series A and Series B Cu... |
| 22.12.2021 | XOMA : 2021 Year-end Letter to Shareholders | Dear Shareholders and Friends, As we close out 2021 and look forward to all the possibilities 2022 will bring for XOMA, it seems appropriate to reflect on how much progress has been made by both our partners and our team. Today, within the ... |
Show more